Mechanisms of resistance to targeted therapy in urothelial carcinoma
Fibroblast growth factor receptor 3 (FGFR3) signalling is altered in ~80% of non-muscle-invasive and ~40% of muscle-invasive bladder cancers via activating mutations (point mutations or gene fusions), overexpression or both. FGFR inhibitors have entered clinical trials in advanced bladder cancer. As...
| Main Author: | |
|---|---|
| Other Authors: | |
| Published: |
University of Leeds
2018
|
| Subjects: | |
| Online Access: | https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.758339 |